BUILDING pharmaceutical quality directly into the supply chain via rigorous upstream validation, rather than simply relying on final product inspections, is essential to securing for public health and safety.
This was emphasized by Kathlyn Rose Reyes, head of supplier quality management at United Laboratories Inc. (Unilab) at The Manila Times Health Forum “Regulating Trust: Ensuring Quality, Safety, and Effectiveness in Medicines.” She emphasized that safeguarding public health requires meticulous scientific controls long before raw materials reach the manufacturing floor.
Reyes explained that establishing pharmaceutical safety begins with strict supplier qualification protocols. This means screening raw chemical inputs, primary packaging materials, and even imported finished items through a strict and objective evaluation matrix that includes formal risk assessments, technical capacity testing, and comprehensive facility auditing. Verifying material integrity at the point of origin prevents contamination and composition defects that pose severe risks to production.
A critical component of this upstream verification process relies on extensive bioequivalence and bioavailability testing. For example, two vital pharmacokinetic parameters are used to confirm generic drug formulations perform identically to their brand-name innovator counterparts. These molecular studies measure the precise rate and extent to which an active ingredient absorbs into the human bloodstream, ensuring both treatments achieve equivalent exposure and therapeutic outcomes.
Maintaining chemical stability presents a challenge in the heat and humidity of the Philippines. The tropical climate’s elevated ambient temperatures and high relative humidity can rapidly accelerate the degradation of sensitive compounds. To mitigate these environmental vulnerabilities, raw materials and active components are subjected to rigorous stability auditing before use.
Data generated from these stress tests allow analytical chemists to monitor potential moisture absorption, physical changes, and molecular degradation over time. This continuous tracking guarantees that the therapeutic potency and overall shelf life of each batch of medicine remain completely uncompromised from initial warehouse storage to nationwide consumer distribution.
Operationally, this end-to-end quality assurance architecture spans the entire product lifecycle, connecting initial research and product design with advanced post-market monitoring. Unilab handles this multi-phase enforcement through its dedicated Corporate Quality Assurance team, which is composed of approximately 160 specialized technical professionals who utilize sophisticated diagnostic instrumentation to monitor chemical purity and isolate trace impurities.
For botanical products and materials highly susceptible to environmental toxins, such as evening primrose oil lines, the technical team deploys atomic absorption spectrophotometers to conduct comprehensive heavy metal assays. This testing suite is further augmented by gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, high-performance liquid chromatography, and automated dissolution testers to maintain strict product uniformity.
This structure is directly reflected in the company’s manufacturing and logistical footprint, which complies with globally recognized healthcare standards, including good laboratory practices, good manufacturing practices, and good distribution practices. Specialized production plants leverage high-capacity automated infrastructure, such as precision liquid filling systems and tablet coating machines, to eliminate manual handling errors, ensuring that life-saving medications retain their established pharmaceutical integrity and clinical safety when they reach Filipino consumers.